Varoli Lucilla, Angeli Piero, Buccioni Michela, Burnelli Silvia, Fazio Nicola, Marucci Gabriella, Recanatini Maurizio, Spampinato Santi
Department of Pharmaceutical Sciences, University of Bologna, Via Belmeloro 6, I-40126 Bologna, Italy.
Med Chem. 2008 Mar;4(2):121-8. doi: 10.2174/157340608783789211.
Novel 2-carbonyl analogues of diphenidol (1) - bearing lipophylic 1-substituents (2) - were synthesized starting from previously investigated diphenidol derivatives acting as M(2)-selective muscarinic antagonists. These compounds were tested for receptor binding affinity versus human muscarinic M(1)-M(5) receptors stably expressed in CHO-K1 cells. Their activity in functional assays carried out on CHO-K1 cells expressing human M(4) receptors (CHO-hM(4)) and on classical models of M(1)-M(3) receptors, in guinea pig and rabbit tissue preparations, was also evaluated. Compound 2d showed an affinity of pK(i) = 7.73 at the human M(4)-receptor subtype with selectivity ratios ranging from 31-fold (M(4)/M(5)) to 60-fold (M(4)/M(2)). Interestingly this compound, in CHO-hM(4) cells, blocked the inhibition of forskolin-activated cAMP accumulation produced by carbachol (IC(50)= 61 nM) whereas it was a weak muscarinic antagonist in functional tests carried out in guinea-pig and rabbit tissue expressing M(1) (pK(b) = 5.96), M(2) (pK(b) = 6.43) and M(3) (pK(b) = 6.09) receptors. In conclusion, the modifications performed in this work on reference compounds led us to obtain surprisingly a M(4) selective antagonist. Considering the therapeutic indications for M(4) selective antagonists, compound 2d may serve as a novel lead compound for further optimization.
从先前研究的作为M(2)选择性毒蕈碱拮抗剂的二苯哌利多衍生物出发,合成了新型的二苯哌利多(1)的2-羰基类似物,其带有亲脂性的1-取代基(2)。测试了这些化合物对稳定表达于CHO-K1细胞中的人毒蕈碱M(1)-M(5)受体的受体结合亲和力。还评估了它们在表达人M(4)受体的CHO-K1细胞(CHO-hM(4))以及豚鼠和兔组织制备物中的M(1)-M(3)受体经典模型上进行的功能测定中的活性。化合物2d在人M(4)受体亚型上显示出pK(i)=7.73的亲和力,选择性比率范围为31倍(M(4)/M(5))至60倍(M(4)/M(2))。有趣的是,该化合物在CHO-hM(4)细胞中阻断了卡巴胆碱产生的对福司可林激活的cAMP积累的抑制作用(IC(50)=61 nM),而在表达M(1)(pK(b)=5.96)、M(2)(pK(b)=6.43)和M(3)(pK(b)=6.09)受体的豚鼠和兔组织中进行的功能测试中,它是一种弱毒蕈碱拮抗剂。总之,这项工作中对参考化合物进行的修饰使我们意外地获得了一种M(4)选择性拮抗剂。考虑到M(4)选择性拮抗剂的治疗适应症,化合物2d可作为进一步优化的新型先导化合物。